StreetInsider.com News Articles

Curasight to present at TD Cowen's 46th Annual Health Care Conference in Boston

Tue, 17 Feb 2026 01:58:00 -0500

COPENHAGEN, Denmark, Feb. 17, 2026 /PRNewswire/ -- Curasight A/S (CPH: CURAS) a clinical-stage radiopharmaceutical company pioneering first-in-class uPAR-targeted radioligand platform therapies across multiple aggressive solid tumors, will present recent company progress including the ongoing Phase 1 clinical trial uTREAT® in glioblastoma, at the TD Cowen 46^th Annual Health Care Conference on Tuesday, March 3^rd, 2026, at 11:50 a.m. Eastern Time / 5:50 p.m. CET in Boston.

A live audio webcast will be broadcast over the internet simultaneously and will be available in the investor section on Curasight.com approximately 48 hours after

Curasight to present at TD Cowen's 46th Annual Health Care Conference in Boston

Tue, 17 Feb 2026 01:58:00 -0500

A live audio webcast will be broadcast over the internet simultaneously and will be available in the investor section on Curasight.com approximately 48 hours after

Curasight to present at TD Cowen's 46th Annual Health Care Conference in Boston

Tue, 17 Feb 2026 01:58:00 -0500

A live audio webcast will be broadcast over the internet simultaneously and will be available in the investor section on Curasight.com approximately 48 hours after

Curasight to present at TD Cowen's 46th Annual Health Care Conference in Boston

Tue, 17 Feb 2026 01:58:00 -0500

A live audio webcast will be broadcast over the internet simultaneously and will be available in the investor section on Curasight.com approximately 48 hours after

Curasight to present at TD Cowen's 46th Annual Health Care Conference in Boston

Tue, 17 Feb 2026 01:58:00 -0500

A live audio webcast will be broadcast over the internet simultaneously and will be available in the investor section on Curasight.com approximately 48 hours after

Curasight to present at TD Cowen's 46th Annual Health Care Conference in Boston

Tue, 17 Feb 2026 01:58:00 -0500

A live audio webcast will be broadcast over the internet simultaneously and will be available in the investor section on Curasight.com approximately 48 hours after

Curasight to present at TD Cowen's 46th Annual Health Care Conference in Boston

Tue, 17 Feb 2026 01:58:00 -0500

A live audio webcast will be broadcast over the internet simultaneously and will be available in the investor section on Curasight.com approximately 48 hours after

Curasight to present at TD Cowen's 46th Annual Health Care Conference in Boston

Tue, 17 Feb 2026 01:58:00 -0500

A live audio webcast will be broadcast over the internet simultaneously and will be available in the investor section on Curasight.com approximately 48 hours after

Curasight to present at TD Cowen's 46th Annual Health Care Conference in Boston

Tue, 17 Feb 2026 01:58:00 -0500

A live audio webcast will be broadcast over the internet simultaneously and will be available in the investor section on Curasight.com approximately 48 hours after

Curasight to present at TD Cowen's 46th Annual Health Care Conference in Boston

Tue, 17 Feb 2026 01:58:00 -0500

A live audio webcast will be broadcast over the internet simultaneously and will be available in the investor section on Curasight.com approximately 48 hours after

Curasight reports tumor uptake in brain cancer trial for uTREAT drug

Mon, 12 Jan 2026 13:04:09 -0500

Curasight A/S (Frankfurt: CUS) announced preliminary data from its Phase 1 clinical trial of uTREAT, a radiopharmaceutical treatment for high-grade gliomas, according to a company press release.

The first patient in the trial showed clear uptake of uTREAT in tumor tissue through positron emission tomography imaging. The signal remained visible for at least 24 hours, indicating sustained tumor binding.

The dosimetry readout aligned with company expectations and supports continued enrollment of additional glioblastoma patients. Curasight expects top-line data in the second quarter of 2026.

"The clear tumor uptake and high retention observed in aggressive glioblastoma provide early clinical validation of our uPAR-targeted radiopharmaceutical

Curasight reports tumor uptake in brain cancer trial for uTREAT drug

Mon, 12 Jan 2026 13:04:09 -0500

Curasight A/S (Frankfurt: CUS) announced preliminary data from its Phase 1 clinical trial of uTREAT, a radiopharmaceutical treatment for high-grade gliomas, according to a company press release.

The dosimetry readout aligned with company expectations and supports continued enrollment of additional glioblastoma patients. Curasight expects top-line data in the second quarter of 2026.

"The clear tumor uptake and high retention observed in aggressive glioblastoma provide early clinical validation of our uPAR-targeted radiopharmaceutical

Curasight reports tumor uptake in brain cancer trial for uTREAT drug

Mon, 12 Jan 2026 13:04:09 -0500

Curasight A/S (Frankfurt: CUS) announced preliminary data from its Phase 1 clinical trial of uTREAT, a radiopharmaceutical treatment for high-grade gliomas, according to a company press release.

The dosimetry readout aligned with company expectations and supports continued enrollment of additional glioblastoma patients. Curasight expects top-line data in the second quarter of 2026.

"The clear tumor uptake and high retention observed in aggressive glioblastoma provide early clinical validation of our uPAR-targeted radiopharmaceutical

Curasight Announces Encouraging Preliminary Data from Phase 1 Trial Evaluating First-in-Class Radiopharmaceutical uTREAT in High-Grade Gliomas®

Mon, 12 Jan 2026 13:03:00 -0500

Clear uptake of uTREAT® in aggressive brain cancer (glioblastoma)
Early data support the potential of first-in-class uPAR-targeted theranostic approach to enable more specific diagnosis and more targeted treatment of high-grade gliomas and other uPAR expressing aggressive solid tumors

COPENHAGEN, Denmark, Jan. 12, 2026 /PRNewswire/ -- Curasight A/S ("Curasight" or "the Company" – TICKER: CURAS), a clinical-stage radiopharmaceutical company developing first-in-class drug candidate uTREAT® targeting uPAR (urokinase-type plasminogen activator receptor), the functional driver of invasion, angiogenesis, and metastasis across most solid tumors, today announced encouraging preliminary data from the first

Curasight Announces Encouraging Preliminary Data from Phase 1 Trial Evaluating First-in-Class Radiopharmaceutical uTREAT in High-Grade Gliomas®

Mon, 12 Jan 2026 13:03:00 -0500

Clear uptake of uTREAT® in aggressive brain cancer (glioblastoma)
Early data support the potential of first-in-class uPAR-targeted theranostic approach to enable more specific diagnosis and more targeted treatment of high-grade gliomas and other uPAR expressing aggressive solid tumors
COPENHAGEN, Denmark, Jan. 12, 2026 /PRNewswire/ -- Curasight A/S ("Curasight" or "the Company" – TICKER: CURAS), a clinical-stage radiopharmaceutical company developing first-in-class drug candidate uTREAT® targeting uPAR (urokinase-type plasminogen activator receptor), the functional driver of invasion, angiogenesis, and metastasis across most solid tumors, today announced encouraging preliminary data from the first

Curasight Announces Encouraging Preliminary Data from Phase 1 Trial Evaluating First-in-Class Radiopharmaceutical uTREAT in High-Grade Gliomas®

Mon, 12 Jan 2026 13:03:00 -0500

Clear uptake of uTREAT® in aggressive brain cancer (glioblastoma)
Early data support the potential of first-in-class uPAR-targeted theranostic approach to enable more specific diagnosis and more targeted treatment of high-grade gliomas and other uPAR expressing aggressive solid tumors
COPENHAGEN, Denmark, Jan. 12, 2026 /PRNewswire/ -- Curasight A/S ("Curasight" or "the Company" – TICKER: CURAS), a clinical-stage radiopharmaceutical company developing first-in-class drug candidate uTREAT® targeting uPAR (urokinase-type plasminogen activator receptor), the functional driver of invasion, angiogenesis, and metastasis across most solid tumors, today announced encouraging preliminary data from the first

Curasight Announces Encouraging Preliminary Data from Phase 1 Trial Evaluating First-in-Class Radiopharmaceutical uTREAT in High-Grade Gliomas®

Mon, 12 Jan 2026 13:03:00 -0500

Clear uptake of uTREAT® in aggressive brain cancer (glioblastoma)
Early data support the potential of first-in-class uPAR-targeted theranostic approach to enable more specific diagnosis and more targeted treatment of high-grade gliomas and other uPAR expressing aggressive solid tumors
COPENHAGEN, Denmark, Jan. 12, 2026 /PRNewswire/ -- Curasight A/S ("Curasight" or "the Company" – TICKER: CURAS), a clinical-stage radiopharmaceutical company developing first-in-class drug candidate uTREAT® targeting uPAR (urokinase-type plasminogen activator receptor), the functional driver of invasion, angiogenesis, and metastasis across most solid tumors, today announced encouraging preliminary data from the first

Curasight Announces Encouraging Preliminary Data from Phase 1 Trial Evaluating First-in-Class Radiopharmaceutical uTREAT in High-Grade Gliomas®

Mon, 12 Jan 2026 13:03:00 -0500

Clear uptake of uTREAT® in aggressive brain cancer (glioblastoma)
Early data support the potential of first-in-class uPAR-targeted theranostic approach to enable more specific diagnosis and more targeted treatment of high-grade gliomas and other uPAR expressing aggressive solid tumors
COPENHAGEN, Denmark, Jan. 12, 2026 /PRNewswire/ -- Curasight A/S ("Curasight" or "the Company" – TICKER: CURAS), a clinical-stage radiopharmaceutical company developing first-in-class drug candidate uTREAT® targeting uPAR (urokinase-type plasminogen activator receptor), the functional driver of invasion, angiogenesis, and metastasis across most solid tumors, today announced encouraging preliminary data from the first

Curasight Announces Encouraging Preliminary Data from Phase 1 Trial Evaluating First-in-Class Radiopharmaceutical uTREAT in High-Grade Gliomas®

Mon, 12 Jan 2026 13:03:00 -0500

Clear uptake of uTREAT® in aggressive brain cancer (glioblastoma)
Early data support the potential of first-in-class uPAR-targeted theranostic approach to enable more specific diagnosis and more targeted treatment of high-grade gliomas and other uPAR expressing aggressive solid tumors
COPENHAGEN, Denmark, Jan. 12, 2026 /PRNewswire/ -- Curasight A/S ("Curasight" or "the Company" – TICKER: CURAS), a clinical-stage radiopharmaceutical company developing first-in-class drug candidate uTREAT® targeting uPAR (urokinase-type plasminogen activator receptor), the functional driver of invasion, angiogenesis, and metastasis across most solid tumors, today announced encouraging preliminary data from the first

Curasight to hold Meetings in San Francisco During J.P. Morgan Healthcare Conference Week

Mon, 05 Jan 2026 04:45:00 -0500

COPENHAGEN, Denmark, Jan. 5, 2026 /PRNewswire/ -- Curasight A/S ("Curasight" or "the Company" – (CPH: CURAS) a clinical-stage theranostic company focused on diagnosing and treating certain types of cancers, announced that CEO Ulrich Krasilnikoff and CMO prof. Andreas Kjær will be in San Francisco during the 44^th J.P. Morgan Healthcare Conference being held January 12-15, 2026.

During the week, Curasight management will hold meetings with investors and other industry stakeholders. The meetings will include updates on the Company's clinical progress, including the recent initiation of a

Curasight to hold Meetings in San Francisco During J.P. Morgan Healthcare Conference Week

Mon, 05 Jan 2026 04:45:00 -0500

COPENHAGEN, Denmark, Jan. 5, 2026 /PRNewswire/ -- Curasight A/S ("Curasight" or "the Company" – (CPH: CURAS) a clinical-stage theranostic company focused on diagnosing and treating certain types of cancers, announced that CEO Ulrich Krasilnikoff and CMO prof. Andreas Kjær will be in San Francisco during the 44^th J.P. Morgan Healthcare Conference being held January 12-15, 2026.

During the week, Curasight management will hold meetings with investors and other industry stakeholders. The meetings will include updates on the Company's clinical progress, including the recent initiation of a

Curasight to hold Meetings in San Francisco During J.P. Morgan Healthcare Conference Week

Mon, 05 Jan 2026 04:45:00 -0500

COPENHAGEN, Denmark, Jan. 5, 2026 /PRNewswire/ -- Curasight A/S ("Curasight" or "the Company" – (CPH: CURAS) a clinical-stage theranostic company focused on diagnosing and treating certain types of cancers, announced that CEO Ulrich Krasilnikoff and CMO prof. Andreas Kjær will be in San Francisco during the 44^th J.P. Morgan Healthcare Conference being held January 12-15, 2026.

During the week, Curasight management will hold meetings with investors and other industry stakeholders. The meetings will include updates on the Company's clinical progress, including the recent initiation of a

Curasight to hold Meetings in San Francisco During J.P. Morgan Healthcare Conference Week

Mon, 05 Jan 2026 04:45:00 -0500

COPENHAGEN, Denmark, Jan. 5, 2026 /PRNewswire/ -- Curasight A/S ("Curasight" or "the Company" – (CPH: CURAS) a clinical-stage theranostic company focused on diagnosing and treating certain types of cancers, announced that CEO Ulrich Krasilnikoff and CMO prof. Andreas Kjær will be in San Francisco during the 44^th J.P. Morgan Healthcare Conference being held January 12-15, 2026.

During the week, Curasight management will hold meetings with investors and other industry stakeholders. The meetings will include updates on the Company's clinical progress, including the recent initiation of a

Curasight doses first patient in brain cancer trial with uTREAT therapy

Thu, 18 Dec 2025 13:46:27 -0500

Curasight A/S (Frankfurt: CUS) announced it has dosed the first patient in a Phase 1 trial testing its uTREAT therapy for brain cancer treatment. The company reported no patient safety issues during the dosing.

The trial represents the first clinical study of uTREAT, which belongs to Curasight's therapeutic platform for treating glioblastoma, an aggressive form of brain cancer. The dosing milestone means Curasight now has both its therapeutic and diagnostic platforms in clinical development.

The Phase 1 study aims to investigate uTREAT as a targeted radiopharmaceutical therapy in patients with newly diagnosed or suspected glioblastoma. The trial design incorporates research from earlier

Curasight doses first patient in brain cancer trial with uTREAT therapy

Thu, 18 Dec 2025 13:46:27 -0500

Curasight A/S (Frankfurt: CUS) announced it has dosed the first patient in a Phase 1 trial testing its uTREAT therapy for brain cancer treatment. The company reported no patient safety issues during the dosing.

The trial represents the first clinical study of uTREAT, which belongs to Curasight's therapeutic platform for treating glioblastoma, an aggressive form of brain cancer. The dosing milestone means Curasight now has both its therapeutic and diagnostic platforms in clinical development.

The Phase 1 study aims to investigate uTREAT as a targeted radiopharmaceutical therapy in patients with newly diagnosed or suspected glioblastoma. The trial design incorporates research from earlier